StockData
Neogen Corp logo

Neogen Corp (NEOG) stock

NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026Score 7/3049% above fair value
$11.08+0.18 (+1.65%)

Close on Nov 18, 2026Market cap $2.42BP/E –Yield –

Neogen operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Neogen's operating income for the twelve months ending Aug 31, 2026 was -$7.38M. For fiscal 2026 it was -$21.60M. The highest annual figure on record is $74.17M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2026May 31, 2026-$21.60M–
FY2025May 31, 2025-$1.06B-1910.6%
FY2024May 31, 2024$58.60M+56.2%
FY2023May 31, 2023$37.52M-36.0%
FY2022May 31, 2022$58.62M-21.0%
FY2021May 31, 2021$74.17M+9.8%
FY2020May 31, 2020$67.52M-0.8%
FY2019May 31, 2019$68.09M-3.0%
FY2018May 31, 2018$70.19M+8.1%
FY2017May 31, 2017$64.95M+15.2%
FY2016May 31, 2016$56.39M+6.2%
FY2015May 31, 2015$53.12M+22.4%
FY2014May 31, 2014$43.39M+6.6%
FY2013May 31, 2013$40.71M+20.6%
FY2012May 31, 2012$33.74M-5.8%
FY2011May 31, 2011$35.84M+33.3%
FY2010May 31, 2010$26.88M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ3 2026Aug 31, 2026-$1.80M–
Q4 FY2026CQ2 2026May 31, 2026$3.10M–
Q3 FY2026CQ1 2026Feb 28, 2026-$3.30M-161.1%
Q2 FY2026CQ4 2025Nov 30, 2025-$5.38M–
Q1 FY2026CQ3 2025Aug 31, 2025-$16.10M-813.3%
Q4 FY2025CQ2 2025May 31, 2025-$611.20M-4809.9%
Q3 FY2025CQ1 2025Feb 28, 2025$5.40M-55.1%
Q2 FY2025CQ4 2024Nov 30, 2024-$457.48M-3262.7%
Q1 FY2025CQ3 2024Aug 31, 2024$2.26M-88.2%
Q4 FY2024CQ2 2024May 31, 2024$12.98M-44.6%
Q3 FY2024CQ1 2024Feb 29, 2024$12.02M-23.3%
Q2 FY2024CQ4 2023Nov 30, 2023$14.47M–
Q1 FY2024CQ3 2023Aug 31, 2023$19.14M+215.7%
Q4 FY2023CQ2 2023May 31, 2023$23.43M+29.9%
Q3 FY2023CQ1 2023Feb 28, 2023$15.68M+145.9%
Q2 FY2023CQ4 2022Nov 30, 2022-$7.66M-161.4%
Q1 FY2023CQ3 2022Aug 31, 2022$6.06M-72.1%
Q4 FY2022CQ2 2022May 31, 2022$18.03M-11.0%
Q3 FY2022CQ1 2022Feb 28, 2022$6.38M-59.6%
Q2 FY2022CQ4 2021Nov 30, 2021$12.47M-35.2%
Q1 FY2022CQ3 2021Aug 31, 2021$21.75M+15.1%
Q4 FY2021CQ2 2021May 31, 2021$20.26M+1.6%
Q3 FY2021CQ1 2021Feb 28, 2021$15.77M+20.9%
Q2 FY2021CQ4 2020Nov 30, 2020$19.25M+5.3%
Q1 FY2021CQ3 2020Aug 31, 2020$18.90M+16.2%
Q4 FY2020CQ2 2020May 31, 2020$19.94M+6.5%
Q3 FY2020CQ1 2020Feb 29, 2020$13.04M-10.9%
Q2 FY2020CQ4 2019Nov 30, 2019$18.27M+0.1%
Q1 FY2020CQ3 2019Aug 31, 2019$16.26M-1.3%
Q4 FY2019CQ2 2019May 31, 2019$18.73M-5.7%
Q3 FY2019CQ1 2019Feb 28, 2019$14.64M-8.0%
Q2 FY2019CQ4 2018Nov 30, 2018$18.25M+1.4%
Q1 FY2019CQ3 2018Aug 31, 2018$16.48M+0.3%
Q4 FY2018CQ2 2018May 31, 2018$19.86M+4.5%
Q3 FY2018CQ1 2018Feb 28, 2018$15.91M+10.9%
Q2 FY2018CQ4 2017Nov 30, 2017$18.00M+6.8%
Q1 FY2018CQ3 2017Aug 31, 2017$16.42M–
Q4 FY2017CQ2 2017May 31, 2017$19.00M–
Q3 FY2017CQ1 2017Feb 28, 2017$14.35M–
Q2 FY2017CQ4 2016Nov 30, 2016$16.85M–

More Neogen figures

See a number that looks wrong?